AU-15330

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AU-15330 是 SWI/SNF ATP 酶亚基 SMARCA2 和 SMARCA4 的蛋白水解靶向嵌合体 (PROTAC) 降解剂。AU-15330 在前列腺癌异种移植模型中诱导有效抑制肿瘤生长，并与 AR 拮抗剂 enzalutamide 协同作用。AU-15330 在去势抵抗性前列腺癌 (CRPC) 模型中诱导疾病缓解而无毒性。

AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity.

——

Animal Model:Six-week-old male CB17 severe combined immunodeficiency (SCID) miceDosage:10 and 30 mg/kg Administration:i.v. (5 days per week for 3 weeks)Result:Showed no evident toxicity in immuno-competent mice.Animal Model:VCaP castration-resistant tumour model (six-week-old male CB17 severe combined immunodeficiency (SCID) mice)Dosage:60 mg/kg with or without 10?mg/kg enzalutamideAdministration:i.v. (3 days per week); p.o. (5 days per week for 5 weeks)Result:Resulted inhibition of tumor growth and triggered disease regression in more than 20% of animals. Combinatorial regimen induced the most potent anti-tumour effect, with regression in all animals.Animal Model:C4-2B non-castrated tumour model (six-week-old male CB17 severe combined immunodeficiency (SCID) mice)Dosage:60 mg/kg with or without 30?mg/kg enzalutamide Administration:i.v. (3 days per week); p.o. (5 days per week for 4 weeks) Result:Strongly inhibited the growth of C4-2B cell line-derived CRPC xenografts in intact mice as a single agent and synergized with enzalutamide.

——

Others

Other Targets

PROTACs | Epigenetic Reader Domain

——

——

2380274-50-8

755.93

C39H49N9O5S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 140 mg/mL (185.20 mM; 超声助溶 )

C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)CN1CCN(CC1)c1cc(nnc1N)-c1ccccc1O)C(C)(C)C)c1ccc(cc1)-c1scnc1C

——

(-20℃)

With Ice Pack

≥ 2 years